The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1)

NCT06424210 | Completed

• 1 other identifier: 202211084RIND
• Study Type: observational
• Target: 163
• Locations: 1 country
• Sites: 1

Brief Summary

Treatment of stage IV esophageal cancer is traditionally palliative, but treatment response is usually poor. The role of surgery in the treatment of advanced esophageal cancer remains controversial. We sought to determine whether surgical treatment followed by neoadjuvant chemoradiation therapy might provide survival benefits for these patients. A retrospective review of esophageal cancer patients with M1 disease treated at National Taiwan University Hospital was performed from April 2002 to June 2021. Patient demographics and cancer staging, treatment, and disease recurrence, and time of follow up were included for analysis. Univariate and multivariate analysis was performed for overall survival and progression-free survival analysis. Propensity score matching based on patient age and tumor staging characteristics was also performed for analysis.

Conditions

Esophageal Cancer; Metastatic Disease

Outcome Measures

Primary Outcomes (1)

• Overall survival and progression-free survival

  Overall survival (OS) and progression-free survival (PFS) curves of patients with or without esophagectomy in the entire study cohort of stage IV esophageal cancer with distant metastasis.

  5 years

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study enrolled a cohort of patients diagnosed with stage IV esophageal cancer who had tumor metastasis to distant organs, including lymph node metastasis detected in the retroperitoneum, which could not be eradicated by surgery, from April 2002 to June 2021 in a tertiary medical center.

You may qualify if:

• Stage IV Esophageal Cancer patients
• Patients were treated with chemoradiation therapy (CCRT)

You may not qualify if:

• Not Stage IV Esophageal Cancer patients
• Patients were not treated with chemoradiation therapy (CCRT)

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospital

Taipei, Zhongzheng, 100, Taiwan

Location

MeSH Terms

Conditions

Esophageal Neoplasms; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Jang-Ming Lee

  National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 13, 2024
• First Posted: May 22, 2024
• Study Start: February 15, 2023
• Primary Completion: June 1, 2023
• Study Completion: June 1, 2023
• Last Updated: May 22, 2024

Record last verified: 2023-02

Locations

TW (1)